|
1
|
Stocker JT: Hepatoblastoma. Semin Diagn
Pathol. 11:136–143. 1994.PubMed/NCBI
|
|
2
|
Schoofs G, Braeye L, Vanheste R,
Verswijvel G, Debiec-Rychter M and Sciot R: Hepatic
rhabdomyosarcoma in an adult: A rare primary malignant liver tumor.
Case report and literature review. Acta Gastroenterol Belg.
74:576–581. 2011.
|
|
3
|
Czauderna P, Lopez-Terrada D, Hiyama E,
Haberle B, Malogolowkin MH and Meyers RL: Hepatoblastoma state of
the art: Pathology, genetics, risk stratification, and
chemotherapy. Curr Opin Pediatr. 26:19–28. 2014. View Article : Google Scholar
|
|
4
|
Davies JQ, de la Hall PM, Kaschula RO,
Sinclair-Smith CC, Hartley P, Rode H and Millar AJ: Hepatoblastoma
- evolution of management and outcome and significance of histology
of the resected tumor. A 31-year experience with 40 cases. J
Pediatr Surg. 39:1321–1327. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang YT, Feng LH, Zhong XD, Wang LZ and
Chang J: Single-agent cisplatin treatment of children with
high-risk hepatoblastoma. J Pediatr Hematol Oncol. 36:271–275.
2014. View Article : Google Scholar
|
|
6
|
Qayed M and Katzenstein HM: Dose-intensive
cisplatin for hepatoblastoma: Have you heard? Lancet Oncol.
14:791–792. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Colnaghi R, Connell CM, Barrett RM and
Wheatley SP: Separating the anti-apoptotic and mitotic roles of
survivin. J Biol Chem. 281:33450–33456. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Altieri DC: Validating survivin as a
cancer therapeutic target. Nat Rev Cancer. 3:46–54. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Duffy MJ, O’Donovan N, Brennan DJ,
Gallagher WM and Ryan BM: Survivin: A promising tumor biomarker.
Cancer Lett. 249:49–60. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ambrosini G, Adida C and Altieri DC: A
novel anti-apoptosis gene, survivin, expressed in cancer and
lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Asechi H, Hatano E, Nitta T, Tada M,
Iwaisako K, Tamaki N, Nagata H, Narita M, Yanagida A, Ikai I, et
al: Resistance to cisplatin-induced apoptosis via PI3K-dependent
survivin expression in a rat hepatoma cell line. Int J Oncol.
37:89–96. 2010.PubMed/NCBI
|
|
12
|
Chandele A, Prasad V, Jagtap JC, Shukla R
and Shastry PR: Upregulation of survivin in G2/M cells and
inhibition of caspase 9 activity enhances resistance in
staurosporine-induced apoptosis. Neoplasia. 6:29–40. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tirro E, Consoli ML, Massimino M, Manzella
L, Frasca F, Sciacca L, Vicari L, Stassi G, Messina L, Messina A,
et al: Altered expression of c-IAP1, survivin, and Smac contributes
to chemotherapy resistance in thyroid cancer cells. Cancer Res.
66:4263–4272. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zaffaroni N, Pennati M, Colella G, Perego
P, Supino R, Gatti L, Pilotti S, Zunino F and Daidone MG:
Expression of the anti-apoptotic gene survivin correlates with
taxol resistance in human ovarian cancer. Cell Mol Life Sci.
59:1406–1412. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kunze D, Erdmann K, Froehner M, Wirth MP
and Fuessel S: siRNA-mediated inhibition of antiapoptotic genes
enhances chemotherapy efficacy in bladder cancer cells. Anticancer
Res. 32:4313–4318. 2012.PubMed/NCBI
|
|
16
|
Hayashi N, Asano K, Suzuki H, Yamamoto T,
Tanigawa N, Egawa S and Manome Y: Adenoviral infection of survivin
antisense sensitizes prostate cancer cells to etoposide in vivo.
Prostate. 65:10–19. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nakahara T, Kita A, Yamanaka K, Mori M,
Amino N, Takeuchi M, Tominaga F, Hatakeyama S, Kinoyama I,
Matsuhisa A, et al: YM155, a novel small-molecule survivin
suppressant, induces regression of established human
hormone-refractory prostate tumor xenografts. Cancer Res.
67:8014–8021. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kawano H, Shakushiro K, Nakata M, Kita A,
Maeda A, Watanabe S, Sako K and Oku N: Antitumor efficacy and
biodistribution of liposomal sepantronium bromide (YM155), a novel
small-molecule survivin suppressant. Eur J Pharm Biopharm.
88:283–289. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nakahara T, Kita A, Yamanaka K, Mori M,
Amino N, Takeuchi M, Tominaga F, Kinoyama I, Matsuhisa A, Kudou M,
et al: Broad spectrum and potent antitumor activities of YM155, a
novel small-molecule survivin suppressant, in a wide variety of
human cancer cell lines and xenograft models. Cancer Sci.
102:614–621. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Minematsu T, Iwai M, Sugimoto K, Shirai N,
Nakahara T, Usui T and Kamimura H: Carrier-mediated uptake of
1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium
bromide (YM155 monobromide), a novel small-molecule survivin
suppressant, into human solid tumor and lymphoma cells. Drug Metab
Dispos. 37:619–628. 2009. View Article : Google Scholar
|
|
21
|
Kita A, Nakahara T, Yamanaka K, Nakano K,
Nakata M, Mori M, Kaneko N, Koutoku H, Izumisawa N and Sasamata M:
Antitumor effects of YM155, a novel survivin suppressant, against
human aggressive non-Hodgkin lymphoma. Leuk Res. 35:787–792. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tolcher AW, Quinn DI, Ferrari A, Ahmann F,
Giaccone G, Drake T, Keating A and de Bono JS: A phase II study of
YM155, a novel small-molecule suppressor of survivin, in
castration-resistant taxane-pretreated prostate cancer. Ann Oncol.
23:968–973. 2012. View Article : Google Scholar
|
|
23
|
Giaccone G, Zatloukal P, Roubec J, Floor
K, Musil J, Kuta M, van Klaveren RJ, Chaudhary S, Gunther A and
Shamsili S: Multicenter phase II trial of YM155, a small-molecule
suppressor of survivin, in patients with advanced, refractory,
non-small-cell lung cancer. J Clin Oncol. 27:4481–4486. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lewis KD, Samlowski W, Ward J, Catlett J,
Cranmer L, Kirkwood J, Lawson D, Whitman E and Gonzalez R: A
multicenter phase II evaluation of the small molecule survivin
suppressor YM155 in patients with unresectable stage III or IV
melanoma. Invest New Drugs. 29:161–166. 2011. View Article : Google Scholar
|
|
25
|
Kumar B, Yadav A, Lang JC, Cipolla MJ,
Schmitt AC, Arradaza N, Teknos TN and Kumar P: YM155 reverses
cisplatin resistance in head and neck cancer by decreasing
cytoplasmic survivin levels. Mol Cancer Ther. 11:1988–1998. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang K, Li Y, Liu W, Gao X and Zhang K:
Silencing survivin expression inhibits the tumor growth of
non-small-cell lung cancer cells in vitro and in vivo. Mol Med Rep.
11:639–644. 2015.
|
|
27
|
Ito R, Asami S, Motohashi S, Ootsuka S,
Yamaguchi Y, Chin M, Shichino H, Yoshida Y, Nemoto N, Mugishima H,
et al: Significance of survivin mRNA expression in prognosis of
neuroblastoma. Biol Pharm Bull. 28:565–568. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kappler M, Köhler T, Kampf C,
Diestelkötter P, Würl P, Schmitz M, Bartel F, Lautenschläger C,
Rieber EP, Schmidt H, et al: Increased survivin transcript levels:
an independent negative predictor of survival in soft tissue
sarcoma patients. Int J Cancer. 95:360–363. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Uehara S, Oue T, Kawatsu M, Nara K and
Fukuzawa M: Increased expression of survivin in hepatoblastoma
after chemotherapy. Eur J Pediatr Surg. 23:400–404. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mita AC, Mita MM, Nawrocki ST and Giles
FJ: Survivin: Key regulator of mitosis and apoptosis and novel
target for cancer therapeutics. Clin Cancer Res. 14:5000–5005.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ryan BM, O’Donovan N and Duffy MJ:
Survivin: A new target for anti-cancer therapy. Cancer Treat Rev.
35:553–562. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nakahara T, Yamanaka K, Hatakeyama S, Kita
A, Takeuchi M, Kinoyama I, Matsuhisa A, Nakano K, Shishido T,
Koutoku H, et al: YM155, a novel survivin suppressant, enhances
taxane-induced apoptosis and tumor regression in a human Calu 6
lung cancer xenograft model. Anticancer Drugs. 22:454–462. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kaneko N, Mitsuoka K, Amino N, Yamanaka K,
Kita A, Mori M, Miyoshi S and Kuromitsu S: Combination of YM155, a
survivin suppressant, with bendamustine and rituximab: A new
combination therapy to treat relapsed/refractory diffuse large
B-cell lymphoma. Clin Cancer Res. 20:1814–1822. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liang H, Zhang L, Xu R and Ju XL:
Silencing of survivin using YM155 induces apoptosis and
chemosensitization in neuroblastomas cells. Eur Rev Med Pharmacol
Sci. 17:2909–2915. 2013.PubMed/NCBI
|
|
35
|
Tamm I, Wang Y, Sausville E, Scudiero DA,
Vigna N, Oltersdorf T and Reed JC: IAP-family protein survivin
inhibits caspase activity and apoptosis induced by Fas (CD95), Bax,
caspases, and anticancer drugs. Cancer Res. 58:5315–5320.
1998.PubMed/NCBI
|
|
36
|
Yamanaka K, Nakahara T, Yamauchi T, Kita
A, Takeuchi M, Kiyonaga F, Kaneko N and Sasamata M: Antitumor
activity of YM155, a selective small-molecule survivin suppressant,
alone and in combination with docetaxel in human malignant melanoma
models. Clin Cancer Res. 17:5423–5431. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Graf RP, Keller N, Barbero S and Stupack
D: Caspase-8 as a regulator of tumor cell motility. Curr Mol Med.
14:246–254. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Feng W, Yoshida A and Ueda T: YM155
induces caspase-8 dependent apoptosis through downregulation of
survivin and Mcl-1 in human leukemia cells. Biochem Biophys Res
Commun. 435:52–57. 2013. View Article : Google Scholar : PubMed/NCBI
|
